The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...

Alongside rate cuts, looser purse strings bode well for a reprise in private equity activity. But it is not a slam dunk. Valuations for sponsor-led transactions are also rising, meaning that despite ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

BNY Mellon Income Stock Fund (Class I shares) underperformed its benchmark, the Dow Jones U.S. Select Dividend Index, during ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth ...

Healthcare is always a hot-button topic discussed during election years. This election cycle is no different, especially for ...

The 2024 edition of Managing IP’s Rising Stars and Corporate IP Stars rankings, produced by Managing IP’s accreditation title ...